Scarica l'app Stockscreener
19.89
0.70%
-0.14
Pre-mercato:
18.41
-1.48
-7.44%
Precedente Chiudi:
$20.03
Aprire:
$19.98
Volume 24 ore:
400.37K
Relative Volume:
1.45
Capitalizzazione di mercato:
$896.44M
Reddito:
-
Utile/perdita netta:
$-85.21M
Rapporto P/E:
-10.52
EPS:
-1.89
Flusso di cassa netto:
$-68.53M
1 W Prestazione:
+8.87%
1M Prestazione:
+15.71%
6M Prestazione:
-20.18%
1 anno Prestazione:
-16.67%
Intervallo 1D:
$19.53
$20.96
Intervallo di 1 settimana:
$17.98
$20.96
Portata 52W:
$13.30
$30.03
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Nome
Enliven Therapeutics Inc
Settore
Industria
Telefono
720-647-8519
Indirizzo
6200 LOOKOUT ROAD, BOULDER
Confronta ELVN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
19.89 | 896.44M | 0 | -85.21M | -68.53M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.16 | 111.66B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.36 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
532.27 | 38.04B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
267.55 | 36.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
219.95 | 25.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-13 | Iniziato | BTIG Research | Buy |
| 2024-09-09 | Iniziato | H.C. Wainwright | Buy |
| 2024-06-11 | Iniziato | Robert W. Baird | Outperform |
| 2024-04-09 | Iniziato | Mizuho | Buy |
| 2023-03-29 | Iniziato | Jefferies | Buy |
Enliven Therapeutics Inc Borsa (ELVN) Ultime notizie
Enliven Therapeutics stock target raised to $40 at H.C. Wainwright By Investing.com - Investing.com India
Tower Research Capital LLC TRC Boosts Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Enliven Reports Breakthrough: 44% Response Rate in CML Drug Trial Surpasses Expectations - Stock Titan
Enliven reports positive Phase 1 trial data for ELVN-001 in CML By Investing.com - Investing.com South Africa
Enliven Therapeutics Says ELVN-001 Shows Favorable Safety And Tolerability Profile - marketscreener.com
Enliven reports positive Phase 1 trial data for ELVN-001 in CML - Investing.com Australia
Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress - The Malaysian Reserve
(ELVN) Investment Analysis - news.stocktradersdaily.com
Enliven Therapeutics (ELVN) Expected to Announce Earnings on Tuesday - Defense World
Wells Fargo & Company MN Has $375,000 Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Invesco Ltd. Buys 508 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Barclays PLC Has $1.45 Million Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Enliven Therapeutics (NASDAQ:ELVN) Sets New 52-Week Low on Insider Selling - Defense World
JPMorgan Chase & Co. Trims Stock Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Enliven (ELVN) Gains Attention as EHA Data Release Approaches | - GuruFocus
Trading (ELVN) With Integrated Risk Controls - news.stocktradersdaily.com
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stake Lowered by Legal & General Group Plc - Defense World
Enliven Therapeutics chief scientific officer sells $80,365 in stock By Investing.com - Investing.com India
Enliven Therapeutics chief scientific officer sells $80,365 in stock - Investing.com Australia
Enliven Therapeutics Inc (ELVN) shows promising results - uspostnews.com
Enliven Therapeutics: Awaiting Additional Trial Data (NASDAQ:ELVN) - Seeking Alpha
Geode Capital Management LLC Acquires 12,510 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Can you now get a good deal on Enliven Therapeutics Inc’s shares? - uspostnews.com
(ELVN) Trading Report - news.stocktradersdaily.com
Vanguard Group Inc. Purchases 55,283 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stake Boosted by Wellington Management Group LLP - Defense World
KLP Kapitalforvaltning AS Makes New $97,000 Investment in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Ratios Revealed: Decoding Enliven Therapeutics Inc (ELVN)’s Financial Health - DWinneX
Corebridge Financial Inc. Trims Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Enliven Therapeutics COO Anish Patel sells shares worth $120,268 By Investing.com - Investing.com India
Enliven Therapeutics COO Anish Patel sells shares worth $120,268 - Investing.com Australia
Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Wall Street Analysts See a 58.78% Upside in Enliven Therapeutics, Inc. (ELVN): Can the Stock Really Move This High? - MSN
Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting - StreetInsider
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 4.9% After Insider Selling - Defense World
Enliven Therapeutics CFO Benjamin Hohl sells $69,320 in stock By Investing.com - Investing.com UK
Enliven Therapeutics CFO Benjamin Hohl sells $69,320 in stock - Investing.com
Where are the Opportunities in (ELVN) - news.stocktradersdaily.com
Swiss National Bank Increases Stock Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Enliven Therapeutics CFO sells $22,504 in stock By Investing.com - Investing.com Nigeria
Enliven Therapeutics CFO sells $22,504 in stock - Investing.com India
Charles Schwab Investment Management Inc. Grows Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
HC Wainwright Forecasts Strong Price Appreciation for Enliven Therapeutics (NASDAQ:ELVN) Stock - Defense World
Bank of New York Mellon Corp Sells 828 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Enliven Therapeutics chief scientific officer sells $257,575 in stock By Investing.com - Investing.com Canada
Enliven Therapeutics Inc Azioni (ELVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):